Company

Immuron Ltd

ASX:IMC

Immuron Ltd (ASX:IMC, NASDAQ:IMRN) is focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

71 stories · page 4 of 4

Pharma & Biotech

Immuron receives U.S. FDA approval to trial new liver disease treatment

By Proactive 08/11/2013

Pharma & Biotech

Immuron launches fully underwritten A$1.86M capital raising

By Proactive 27/03/2013

Pharma & Biotech

Immuron Limited to go to market

By Proactive 25/03/2013

Pharma & Biotech

Immuron has further success with antibiotic-associated infection prevention drug

By Proactive 04/03/2013

Pharma & Biotech

Immuron enhances balance sheet by A$1.4m to continue commercial rollout of Travelan®

By Proactive 18/06/2012

Pharma & Biotech

Immuron: globalisation of Travelan® continues with over the counter potential in Canada

By Proactive 04/06/2012

Pharma & Biotech

Immuron secures distributor for Travelan® in southeast Asian markets

By Proactive 10/05/2012

Pharma & Biotech

Immuron enters A$1.4m funding agreement to expand Travelan into other territories

By Proactive 16/01/2012

Pharma & Biotech

Immuron receives green light to begin clinical liver disease trial in the U.S.

By Proactive 10/01/2012

Pharma & Biotech

Immuron partners with Harvard Medical School to test its technology in cancer patients

By Proactive 16/12/2011

Media

Small healthcare stocks lead the way: Analytica, Cbio, Allied Healthcare Group and OBJ

By Proactive 30/11/2011